We demonstrated that PEITC was highly effective in eliminating p53-defective CLL cells, even in the presence of bone marrow stromal cells, which usually protect CLL cells from the cytotoxic effect of conventional chemotherapeutic agents. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.